Bibliography
■323
12
Nkoka O, Chuang TW, Chen YH, (2020)
Effects of Malaria Interventions During Pregnancy on Low Birth Weight in Malawi, Am J Prev Med, 59(6):904-913, 2020.
13
Saito M, Briand V, Min AM, McGready R, (2020)
Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs, Lancet Child Adolesc Health,
4(10):761-774, 2020.
14
Bassat Q, Ogutu B, Djimde A, Stricker K, Hamed K., (2015)
Tailoring a pediatric formulation of artemether-lumefantrine for treatment of Plasmodium falciparum malaria. Antimicrobial agents and chemotherapy, 59(8),
4366-4374, 2015.
15
WHO, (2015)
Guidelines for the treatment of malaria, 3rd Edition. World Health Organization, 2015.
16
Nasir B, Shah SN, Murtaza G, Shahid N, Akhtar M, Khan BA, Azhar S, Mumtaz A, Waseem A, Khan SA, Ubaid M., (2012)
New HPLC method for the determination of artemether in injections. Scientific Research and Essays. 7(10):1165-1168, 2012.
17
Byakika-Kibwika P, Lamorde M, Mayanja-Kizza H, Khoo S, Merry C., (2011)
Artemether-lumefantrine combination therapy for treatment of uncomplicated malaria: the potential for complex interactions with antiretroviral drugs in HIV-
infected individuals. Malaria research and Treatment., 2011.
18
Cui L, Su XZ, (2009)
Discovery, mechanisms of action and combination therapy of artemisinin. Expert Review of Anti-Infective Therapy, 7(8):999-1013, 2009.
19
White NJ, (2004)
Antimalarial drug resistance, J Clin Invest, 113:1084–1092, 2004.
20
WHO, (2015)
Global action plan on antimicrobial resistance, Geneva, 2015. https://www.who.int/publications-detail-redirect/global-action-
plan-on-antimicrobial-resistance
21
Staehli Hodel EM, Guidi M, Zanolari B, Mercier T, Duong S, Kabanywanyi AM, Ariey F, Buclin T, Beck HP, Decosterd LA, Olliaro P, Genton B, Csajka C,
(2013)
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients, Malar J, 10;12:235, 2013.
22
Maganda BA, Ngaimisi E, Kamuhabwa AA, Aklillu E, Minzi OM, (2015)
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in
HIV-malaria co-treatment. Malar J. 25;14:179, 2015.
23
Borrmann S, Sallas WM, Machevo S, González R, Björkman A, Mårtensson A, Hamel M, Juma E, Peshu J, Ogutu B, Djimdé A, D’Alessandro U, Marrast
A-M, Lefèvre G, Kern SE, (2010)
The effect of food consumption on lumefantrine bioavailability in African children receiving artemether–lumefantrine crushed or dispersible tablets (Coartem®)
for acute uncomplicated Plasmodium falciparum malaria. Eur J Trop Med Int Health. 15:434-441, 2010.
24
Hietala SF, Mårtensson A, Ngasala B, Dahlström S, Lindegårdh N, Annerberg A, Premji Z, Färnert A, Gil P, Björkman A, Ashton M., (2010)
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum
malaria in Tanzania. Antimicrobial agents and chemotherapy, 54(11), 4780-4788, 2010.
25
White NJ, van Vugt M, Ezzet F., (1999)
Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine. Clin. Pharmacokin. 37:105-125, 1999.
26
Bonica JJ, McDonald JS, (1995)
Principles and Practice of Obstetric Analgesia and Anesthesia. 2nd. Vol. 1995. Baltimore, MD: Williams & Wilkins, 1995.
27
Nakai A, Sekiya I, Oya A, Koshino T, Araki T., (2002)
Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet., 266:25-29, 2002.
28
Feghali M, Venkataramanan R, Caritis S., (2016)
Pharmacokinetics of drugs in pregnancy. Semin Perinatol, 39:512-519, 2016.
29
George B, Lumen A, Nguyen C, Wesley B, Wang J, Beitz J, Crentsil V., (2020)
Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. NPJ Syst Biol Appl., 6:36, 2020.
30
Dellicour S, Sevene E, McGready R, Tinto H, Mosha D, Manyando C, Rulisa S, Desai M, Ouma P, Oneko M, Vala A., (2017)
First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational
studies, PLoS Med 14(5): e1002290, 2017.
31
Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H., (2012)
Physiological, anatomical, and metabolic changes with gestational age during normal pregnancy: creating a database and analysing trends for parameters
required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 51:365–96, 2012.
32
Gaohua L, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A, (2012)
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin
Pharmacol, 74:873-885, 2012.
33
Baselt RC, (2015)
Disposition of Toxic Drugs and Chemicals in Man. 10th Edition. Biomedical Publications, California, p. 162-162 and 1177, 2015.
34
Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD, (2007)
Epidemiology and burden of malaria in pregnancy, Lancet Infect Dis 7:93–104, 2007.